Neuroplasticity in Neurodegenerative Disease

Overview

Neuroplasticity—the brain’s capacity to reorganize its structure, function, and connections in response to experience, injury, or disease—is a fundamental property of the nervous system that plays a dual role in neurodegenerative diseases. On one hand, neuroplastic mechanisms provide compensatory resilience that can delay symptom onset and slow functional decline; on the other, maladaptive plasticity can contribute to disease pathology and aberrant circuit dynamics. Understanding neuroplasticity in the context of neurodegeneration is essential for developing therapeutic interventions that promote beneficial rewiring while suppressing harmful changes. The concept underpins cognitive reserve, rehabilitation strategies, and emerging neuromodulatory therapies for conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS)^{1Exploring the role of neuroplasticity in development, aging, and neurodegeneration2023 · Brain Sciences · DOI 10.3390/brainsci13121610Open reference2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}.

Neuroplasticity Mechanisms in Neurodegeneration

flowchart TD
    A["Neuroplasticity"] --> B["Adaptive<br/>Plasticity"]
    A --> C["Maladaptive<br/>Plasticity"]

    B --> D["Compensatory<br/>Rewiring"]
    B --> E["Cognitive<br/>Reserve"]
    B --> F["Synaptic<br/>Remodeling"]

    D --> G["Delayed<br/>Symptom Onset"]
    E --> H["Slowed<br/>Decline"]
    F --> I["Functional<br/>Recovery"]

    C --> J["Aberrant<br/>Circuit Changes"]
    C --> K["Dysfunctional<br/>Synapses"]
    C --> L["Maladaptive<br/>Sprouting"]

    J --> M["Disease<br/>Progression"]
    K --> N["Hyperexcitability"]
    L --> O["Incorrect<br/>Connections"]

    P["Therapeutic<br/>Intervention"] --> Q["Promote<br/>Adaptive"]
    P --> R["Suppress<br/>Maladaptive"]

    Q --> D
    R --> C

Neuroplasticity in Disease Progression

• Adaptive Plasticity: compensatory mechanisms that provide resilience and slow decline

• Maladaptive Plasticity: aberrant changes that contribute to pathology

• Therapeutic Target: enhance beneficial plasticity while suppressing harmful changes

Types of Neuroplasticity

Neuroplasticity encompasses several distinct but interconnected forms of neural adaptation, each operating at different spatial and temporal scales^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference4Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification2017 · Experimental Neurology · DOI 10.1016/j.expneurol.2017.10.002Open reference}.

Synaptic Plasticity

Synaptic plasticity refers to activity-dependent changes in the strength of synaptic transmission and constitutes the primary cellular mechanism for learning and memory^{5Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease2019 · Nature Medicine · DOI 10.1038/s41591-019-0375-9Open reference}.

• Long-term potentiation (LTP): A persistent strengthening of synaptic transmission following high-frequency stimulation. LTP is mediated primarily through NMDA receptor activation, leading to calcium influx, activation of CaMKII and PKC signaling cascades, and insertion of additional AMPA receptors into the postsynaptic membrane. LTP in the hippocampus is critical for declarative memory formation and is severely impaired in Alzheimer’s disease^{6A synaptic model of memory: long-term potentiation in the hippocampus1993 · Nature · DOI 10.1038/361031a0Open reference}.

• Long-term depression (LTD): A sustained decrease in synaptic efficacy triggered by low-frequency stimulation or specific patterns of activity. LTD is essential for synaptic refinement, memory flexibility, and preventing saturation of synaptic weights. Aberrant LTD has been implicated in the early synaptic loss characteristic of Alzheimer’s disease, where soluble amyloid-beta oligomers facilitate excessive LTD while inhibiting LTP^{7Alzheimer's disease is a synaptic failure2002 · Science · DOI 10.1126/science.1074069Open reference}.

• Spike-timing-dependent plasticity (STDP): A form of Hebbian learning where the precise temporal order of pre- and postsynaptic action potentials determines whether synapses are strengthened or weakened. STDP is disrupted in several neurodegenerative conditions, contributing to circuit dysfunction^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}.

• Homeostatic plasticity: Compensatory mechanisms that maintain neural circuit stability by scaling synaptic strengths up or down in response to prolonged changes in activity. Synaptic scaling, a key form of homeostatic plasticity, is mediated through BDNF signaling and TNF-alpha release from astrocytes. Failure of homeostatic plasticity may contribute to neuronal hyperexcitability observed in early-stage neurodegeneration^{8Neuroplasticity and nervous system recovery: cellular mechanisms, therapeutic advances, and future prospects2025 · Neural Regeneration ResearchOpen reference}.

Structural Plasticity

Structural plasticity involves physical changes to neuronal morphology and connectivity^{9Adult neurogenesis in neurodegenerative diseases2015 · Cold Spring Harbor Perspectives in Biology · DOI 10.1101/cshperspect.a021287Open reference}:

• Dendritic remodeling: Alterations in dendritic spine density, morphology, and branching patterns in response to activity or injury. Dendritic spine loss is one of the earliest pathological changes in Alzheimer’s disease, preceding neuronal death by years. Spine density reductions of 25-35% are observed in the prefrontal cortex and hippocampus of AD patients^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}0.

• Axonal sprouting: The growth of new axonal branches from surviving neurons to reinnervate denervated targets. While potentially compensatory, aberrant sprouting can create dysfunctional circuits. In Parkinson’s disease, sprouting of serotonergic neurons into the denervated striatum can cause levodopa-induced dyskinesias^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}1.

• Synaptogenesis: The formation of new synaptic connections between neurons. Activity-dependent synaptogenesis in unaffected brain regions can partially compensate for synaptic loss in diseased areas, contributing to cognitive reserve^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}2.

Adult Neurogenesis

The generation of new neurons in the adult brain, primarily in the subgranular zone of the dentate gyrus (hippocampal neurogenesis) and the subventricular zone (olfactory neurogenesis), represents a form of structural plasticity^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}3^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}4.

• In the healthy adult brain, approximately 700 new neurons are generated daily in the hippocampus, integrating into existing circuits and contributing to pattern separation and memory encoding.

• Hippocampal neurogenesis declines with aging and is further reduced in Alzheimer’s disease, correlating with memory impairment. Tau hyperphosphorylation in the dentate gyrus particularly impairs neurogenesis^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}5.

• In Parkinson’s disease, dopaminergic denervation reduces neurogenesis in both neurogenic niches, although compensatory increases have been observed in some animal models^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}6.

• Exercise, environmental enrichment, and certain pharmacological agents (including antidepressants and BDNF mimetics) can enhance adult neurogenesis, offering potential therapeutic avenues^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}7.

Functional Reorganization

At the network level, functional reorganization involves the recruitment of alternative brain regions or circuits to compensate for damaged areas^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}8:

• Vicariation: Intact brain regions assume functions previously performed by damaged areas. PET and fMRI studies in early Alzheimer’s disease show increased activation of prefrontal cortex regions during memory tasks, compensating for declining hippocampal function^{2The intersection of amyloid and tau pathology in Alzheimer's disease2014 · Neuron · DOI 10.1016/j.neuron.2014.05.004Open reference}9.

• Diaschisis and recovery: Remote effects of focal brain damage on connected regions, followed by gradual functional recovery through network reorganization.

• Cross-modal plasticity: Sensory cortical areas can be recruited for processing of other modalities following deafferentation.

Neuroplasticity in Specific Neurodegenerative Diseases

Alzheimer’s Disease

In Alzheimer’s disease, neuroplasticity is compromised at multiple levels. Soluble amyloid-beta oligomers directly impair synaptic dysfunction by inhibiting LTP and facilitating LTD, even before the formation of amyloid plaques. Tau pathology disrupts axonal transport of essential plasticity molecules including BDNF and synaptic vesicle components. Despite these impairments, compensatory neuroplastic mechanisms operate throughout disease progression^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}0^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}1:

• Preclinical stage: Increased synaptic density and enhanced functional connectivity in some regions compensate for emerging pathology, potentially explaining the decades-long presymptomatic period in many individuals.

• MCI stage: Recruitment of additional frontal and parietal networks during cognitive tasks, reflecting compensatory functional reorganization that delays clinical decline.

• Dementia stage: Progressive failure of compensatory mechanisms as pathological burden overwhelms plastic capacity, leading to accelerating cognitive deterioration.

The concept of cognitive reserve—the idea that higher education, intellectual engagement, and social activity build resilient neural networks—is fundamentally a neuroplasticity phenomenon^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}2^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}3.

Parkinson’s Disease

Parkinson’s disease involves progressive loss of dopaminergic neurons in the substantia nigra, but clinical symptoms typically do not manifest until 50-70% of these neurons are lost, reflecting remarkable compensatory plasticity in the nigrostriatal system^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}4

• Dopaminergic compensation: Surviving neurons increase dopamine synthesis and release, upregulate dopamine receptors, and extend axonal arbors to maintain striatal dopamine levels.

• GABAergic circuit reorganization: Basal ganglia circuits undergo extensive reorganization, with changes in the indirect and hyperdirect pathways partially compensating for striatal dopamine depletion.

• Cortical compensation: Motor cortical regions show increased recruitment during movement execution, reflecting compensatory functional plasticity.

• Maladaptive plasticity: Chronic levodopa treatment can induce aberrant LTP at corticostriatal synapses, contributing to levodopa-induced dyskinesias—a prime example of maladaptive neuroplasticity.

Huntington’s Disease

In Huntington’s disease, the mutant huntingtin protein disrupts multiple plasticity mechanisms, including BDNF transcription and transport, corticostriatal LTP, and adult neurogenesis. The medium spiny neurons of the striatum are particularly vulnerable due to their dependence on cortically-derived BDNF for survival and synaptic maintenance^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}5^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}6.

Amyotrophic Lateral Sclerosis

In ALS, cortical hyperexcitability—a form of maladaptive plasticity—precedes motor neuron degeneration and may contribute to disease pathogenesis through excitotoxicity. Compensatory reinnervation of denervated muscle fibers by surviving motor neurons (collateral sprouting) temporarily maintains motor function but eventually fails as the disease progresses^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}7^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}8.

Molecular Mediators of Neuroplasticity

Neurotrophic Factors

Neurotrophic factors are critical regulators of neuroplasticity^{3Dynamic brains and the changing rules of neuroplasticity: implications for learning and recovery2017 · Frontiers in Psychology · DOI 10.3389/fpsyg.2017.01657Open reference}9:

• BDNF: The most extensively studied neurotrophin in neurodegeneration. BDNF binds TrkB receptors to activate PI3K/Akt, MAPK/ERK, and PLCγ signaling cascades, promoting synaptic plasticity, neuronal survival, and adult neurogenesis. BDNF levels are reduced in the hippocampus and cortex of Alzheimer’s disease patients and in the substantia nigra of Parkinson’s disease patients^{4Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification2017 · Experimental Neurology · DOI 10.1016/j.expneurol.2017.10.002Open reference}0.

• GDNF (Glial cell-derived neurotrophic factor): Essential for the survival and maintenance of dopaminergic neurons, making it a key therapeutic target in Parkinson’s disease.

• NGF (Nerve growth factor): Critical for cholinergic neuron survival in the nucleus basalis of Meynert, which degenerates early in Alzheimer’s disease.

Epigenetic Regulation

Epigenetic mechanisms modulate neuroplasticity gene expression:

• Histone acetylation: Activity-dependent histone acetylation at plasticity gene promoters (BDNF, Arc, CREB) facilitates LTP and memory consolidation. Histone deacetylase (HDAC) inhibitors can rescue plasticity deficits in animal models of neurodegeneration.

• DNA methylation: Dynamic DNA methylation at CpG sites regulates neuroplasticity genes. Aberrant methylation patterns at BDNF and synaptic gene promoters are observed in Alzheimer’s disease.

• Non-coding RNAs: MicroRNAs (miR-132, miR-134, miR-9) regulate dendritic spine morphology and synaptic plasticity.

Glial Cell Contributions

Astrocytes and microglia modulate synaptic plasticity through cytokine release, trophic factor secretion, and direct structural interactions. Neuroinflammation in neurodegeneration disrupts these glial functions, contributing to synaptic loss.

Therapeutic Implications

Non-Invasive Brain Stimulation

• Transcranial magnetic stimulation: Repetitive TMS can modulate cortical excitability and promote LTP-like plasticity. Clinical trials show modest cognitive improvements in Alzheimer’s disease patients with multi-session TMS targeting the dorsolateral prefrontal cortex and parietal regions.

• Transcranial direct current stimulation (tDCS): Low-intensity electrical stimulation that modulates neuronal excitability. Studies show improved motor learning in Parkinson’s disease and enhanced memory in early Alzheimer’s disease^{4Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification2017 · Experimental Neurology · DOI 10.1016/j.expneurol.2017.10.002Open reference}1.

Pharmacological Approaches

• BDNF mimetics: Small molecule TrkB agonists (e.g., 7,8-dihydroxyflavone, LM22A-4) that cross the blood-brain barrier and promote plasticity signaling.

• HDAC inhibitors: Enhance synaptic plasticity gene expression and rescue memory deficits in preclinical neurodegeneration models.

• mTOR modulators: Rapamycin and rapalogs modulate autophagy and protein synthesis, two processes critical for synaptic plasticity maintenance.

• Cholinesterase inhibitors (donepezil, galantamine, rivastigmine): Enhance cholinergic transmission and modestly improve cortical plasticity in Alzheimer’s disease.

• Memantine: An NMDA receptor antagonist that may protect against excitotoxic damage while preserving physiological synaptic plasticity^{4Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification2017 · Experimental Neurology · DOI 10.1016/j.expneurol.2017.10.002Open reference}2.

Cognitive Training and Enrichment

• Computerized cognitive training programs targeting specific domains (working memory, processing speed, executive function) can produce modest but significant improvements in trained and untrained tasks.

• Multicomponent interventions combining physical exercise, cognitive stimulation, social engagement, and dietary optimization (e.g., the FINGER trial model) show the greatest promise for preserving neuroplasticity in at-risk populations^{4Compensatory mechanisms in Parkinson's disease: circuits adaptations and role in disease modification2017 · Experimental Neurology · DOI 10.1016/j.expneurol.2017.10.002Open reference}3.

Clinical Translation and Therapeutic Implications

The capacity for neuroplasticity represents a fundamental therapeutic target in neurodegenerative disease. While progressive neuronal loss creates structural deficits, the residual neural circuitry retains substantial plastic potential that can be harnessed to maintain function and slow clinical decline.

Therapeutic Approaches Targeting Neuroplasticity

Neurotrophin-based therapies: BDNF mimetics such as 7,8-dihydroxyflavone (7,8-DHF) and LM22A-4 activate TrkB receptors to promote synaptic plasticity and neuronal survival.

Histone deacetylase (HDAC) inhibitors: Compounds such as valproic acid, sodium butyrate, and entinostat (MS-275) enhance histone acetylation at plasticity gene promoters.

Acetylcholinesterase inhibitors: Donepezil, galantamine, and rivastigmine enhance cholinergic transmission, which modulates cortical plasticity and modestly improves cognition in Alzheimer’s disease.

Biomarker Development

Future Directions

Emerging approaches to harnessing neuroplasticity in neurodegeneration include:

• Optogenetic and chemogenetic reactivation of memory engrams in early Alzheimer’s disease, based on evidence that memories may be inaccessible rather than erased.

• Stem cell therapies that provide both trophic support and direct cell replacement to restore circuit function.

• Closed-loop neuromodulation systems that detect aberrant neural activity in real time and deliver precisely timed stimulation to restore normal plasticity patterns.

• Digital therapeutics combining AI-driven personalized cognitive training with wearable neurostimulation devices.

See Also

• Brain-Derived Neurotrophic Factor (BDNF)

• Cognitive Reserve

• Long-Term Potentiation

• Synaptic Dysfunction

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• Neuroplasticity — StatPearls (NCBI)

• Brain Plasticity and Behavior — Annual Review of Psychology

• Allen Brain Atlas — Brain Expression Data